Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

enVVeno Medical (NVNO) Depreciation & Amortization (CF) (2017 - 2020)

enVVeno Medical has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $26297.0 for Q4 2020.

  • Quarterly results put Depreciation & Amortization (CF) at $26297.0 for Q4 2020, down 31.87% from a year ago — trailing twelve months through Dec 2020 was $97549.0 (down 21.12% YoY), and the annual figure for FY2025 was $136000.0, down 28.04%.
  • Depreciation & Amortization (CF) for Q4 2020 was $26297.0 at enVVeno Medical, roughly flat from $26291.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for NVNO hit a ceiling of $38600.0 in Q4 2019 and a floor of $19676.0 in Q1 2020.
  • Median Depreciation & Amortization (CF) over the past 4 years was $33126.5 (2017), compared with a mean of $30066.4.
  • Peak annual rise in Depreciation & Amortization (CF) hit 14.78% in 2019, while the deepest fall reached 32.32% in 2019.
  • enVVeno Medical's Depreciation & Amortization (CF) stood at $33254.0 in 2017, then grew by 1.13% to $33629.0 in 2018, then rose by 14.78% to $38600.0 in 2019, then crashed by 31.87% to $26297.0 in 2020.
  • The last three reported values for Depreciation & Amortization (CF) were $26297.0 (Q4 2020), $26291.0 (Q3 2020), and $25285.0 (Q2 2020) per Business Quant data.